Skip to content
Logo APM
  • 登录
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
    • Māori
高级检索
  • Minimal residual disease negat...
  • 引用
  • 发送短信
  • 推荐此
  • 打印
  • 导出纪录
    • 导出到 RefWorks
    • 导出到 EndNoteWeb
    • 导出到 EndNote
  • 加到收藏夹
  • Permanent link
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Saved in:
书目详细资料
Main Authors: Aurore Perrot, Valérie Lauwers‐Cancès, Jill Corre, Nelly Robillard, Cyrille Hulin, Marie‐Lorraine Chrétien, Thomas Dejoie, Sabrina Mahéo, Anne-Marie Stoppa, Brigitte Pegourié, Lionel Karlin, Laurent Garderet, Bertrand Arnulf, Chantal Doyen, Nathalie Meuleman, Bruno Royer, Jean‐Richard Eveillard, Lotfi Benboubker, Mamoun Dib, Olivier Decaux, Arnaud Jaccard, Karim Belhadj, Sabine Bréchignac, Brigitte Kolb, Cécile Fohrer, Mohamad Mohty, Margaret Macro, Paul G. Richardson, Victoria Carlton, Martin Moorhead, Thomas A. Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi
格式: Artigo
语言:英语
出版: 2018
在线阅读:https://doi.org/10.1182/blood-2018-06-858613
标签: 添加标签
没有标签, 成为第一个标记此记录!
  • 持有资料
  • 实物特征
  • 您的评论
  • 相似书籍
  • 职员浏览

因特网

https://doi.org/10.1182/blood-2018-06-858613

相似书籍

  • Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
    由: Perrot, Aurore, et al.
    出版: (2018)
  • Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study
    由: Murielle Roussel, et al.
    出版: (2016)
  • Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
    由: Xavier Leleu, et al.
    出版: (2013)
  • Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
    由: Dejoie, Thomas, et al.
    出版: (2016)
  • Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
    由: Thomas Dejoie, et al.
    出版: (2016)

检索选项

  • 检索历史
  • 高级检索

查找更多

  • 浏览目录
  • 按字母顺序浏览
  • 新项目

需要帮助?

  • 检索技巧
  • 咨询台
  • 常见问题

Our networks:

  • Facebook Instagram Linkedin Youtube Spotify Tiktok

Developed by

Logo de acervos digitais